Navigation Links
Evotec Starts Phase II in Smoking Cessation with EVT 302
Date:2/28/2008

HAMBURG, Germany and OXFORD, England, February 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B).

This double-blind, three-way cross-over study is designed to investigate the influence of EVT 302 on craving and withdrawal symptoms after short-term deprivation of cigarettes in 90 smokers. Smokers will receive a single dose of EVT 302, nicotine, and placebo in a random order. The effect of EVT 302 on craving when combined with nicotine replacement therapy will be assessed as a secondary outcome. In addition, safety and tolerability as well as additional outcome parameters relating to exposure and MAO-B inhibition will be investigated. The results are expected to be reported in the third quarter of 2008.

Dr John Kemp, Chief Research & Development Officer at Evotec, commented: "Evotec is extremely proud to have progressed its second drug candidate into Phase II clinical trials. I am extremely pleased with the safety and tolerability profile of EVT 302 in young and elderly subjects emerging from Phase I studies and look forward to continued progress with this compound."

This is one of two Phase II studies planned to be initiated in 2008 as part of the clinical development program of EVT 302 in smoking cessation. The second study to access the impact of EVT 302 on the quit rate of heavy smokers withdrawing from cigarettes is expected to start in mid 2008.

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the timing of the completion of the transaction between Evotec and Renovis, the anticipated benefits of the business comb
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment bank KTA Capital,s ...reed an AU$6.7 mil convertible note private placem...e placement was arranged by KTA Capital as Neuren,... New York (PRWEB) November 23, 20... Capital, LLC ("KTA Capital") has announ...
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--Sigma-AldrichCorporati...ferenceonTuesday,December1stat1:45PMGMTinLondon,7:...roadcastovertheInternetavailableat http://inve s..."Webcast"icontoaccessthisfile. ,, AboutSigma-...hTechnologycompany.Itschemicalandbiochemicalproduc...
(Date:11/24/2009)...lif.,Nov.24/PRNewswire-FirstCall/--NeurogesX,Inc.(...evelopingandcommercializingnovelpainmanagementther...dChiefExecutiveOfficer,isscheduledtopresentatthe21...ecember1-2,2009atTheNewYorkPalaceHotelinNewYork,Ne...nancialOfficer,willbeavailabletorespondtoquestions...
(Date:11/24/2009)...cacyendpointhasbeenmetforpatientswithadvanced-stag...Nov.24/PRNewswire-FirstCall/-AEternaZentarisInc.(N...maceuticalcompanyfocusedonendocrinetherapyandoncol...tudywithitstargetedcytotoxicpeptideconjugate,AEZS-...entendometrialcancer.Inapersonalizedhealthcareappr...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...arch 11 Amicus Therapeutics (Nasdaq: FOLD ) tod...f Executive Officer John F. Crowley will be presen... Healthcare Conference. Mr. Crowley,s presentatio...30 a.m. Eastern Time. , , Individuals can listen ...n to the Investors section of the Amicus Therapeut...
...rch 11 Insmed Inc. (Nasdaq: INSM ), a developer...ls, today reported results for the quarter and ful...hlights , , , , Follow-on Biologics ...ive agreement with Merck & Co., Inc. whereby M...ts related to Insmed,s follow-on biologics platfor...
... 11 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; NASD...pointed Praxis Pharmaceutical France SARL,as its F...nostic tool, Aridol. , Praxis Pharmaceutical i...uce a portfolio of respiratory specialist products...ll complete the reimbursement application for,Arid...
Other Biology Technology:Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results 10Pharmaxis Appoints French Distributor for Aridol(TM) 2
(Date:11/24/2009)...r of debate. A high-profile study a few years ago ... carbon from trees and leaves, evidence for a very...osystems. , But new research from the University.... Algae provide a much richer diet for fish and ot...this week in the Proceedings of the National Acad...
(Date:11/23/2009)... evidence that the "synergistic" effect of early-l...tion and indoor endotoxin causes more harm to deve... , Environmental health scientists at the Univ... shown that children exposed to both high levels o...uring early life are six times more likely to expe...
(Date:11/23/2009)...e of day matters to forest trees dealing with drou...ch team led by Professor Malcolm Campbell, Univers...search and colleagues in the department of cell an...Capitalizing on their previous work to decode the ...ned how poplar trees use their 45,000 genes to res...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 1Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 2SRI announces selection by the National Cancer Institute as a Chemical Biology Consortium center 9315 1SRI announces selection by the National Cancer Institute as a Chemical Biology Consortium center 9315 2IOS Press announces launch of Journal of Berry Research 9311 1IOS Press announces launch of Journal of Berry Research 9311 2IOS Press announces launch of Journal of Berry Research 9311 3
...ns National Zoo recently acquired 12,000 new anima...tional Zoo scientists in Puerto Ricoas part of an ...hreatened species. National Zoo scientists hope to...to their wild ocean habitat. , In August, Zoo Rep...rates Keeper Mike Henley traveled to Puerto Rico w...
..., Ph.D., and a team of national collaborators have...he National Institutes of Health (NIH) for their r...tive Substances and Psychosocial Stress. alAbsi i...cal Research Institute at the University of Minnes...among the first of 45 funded by the National Insti...
...nstitute of Transportation Studies (ITS-Davis) wil... Road to,Sustainability: From Research to Practice...ed for federal, state and local government,officia...sers, and,transportation specialists from nonprofi... highway and vehicle technologies; , Transit,s r...
Other Biology News:Smithsonian scientists working to save microscopic threatened species 2Mustafa al'Absi Ph.D. and national team awarded major NIH grant 2
Immunoprecipitation Starter Pack from GE Healthcare, formerly Amersham Biosciences
Prolong Gold Antifade Reagent from Invitrogen
GIBCO Modified Eagle Medium (MEM) (2X); liquid from Invitrogen
FliTrx Panning Kit from Invitrogen
Biology Products: